Edge Therapeutics Inc (EDGE) CEO Sells $27,325.00 in Stock
Edge Therapeutics Inc (NASDAQ:EDGE) CEO Brian A. Leuthner sold 2,500 shares of Edge Therapeutics stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $10.93, for a total transaction of $27,325.00. Following the transaction, the chief executive officer now directly owns 110,236 shares in the company, valued at $1,204,879.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Edge Therapeutics Inc (EDGE) traded up 0.72% during trading on Wednesday, hitting $11.16. 23,033 shares of the stock were exchanged. Edge Therapeutics Inc has a 52 week low of $7.30 and a 52 week high of $13.50. The firm’s 50 day moving average price is $10.20 and its 200-day moving average price is $9.97. The stock’s market cap is $344.30 million.
Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.44). On average, analysts predict that Edge Therapeutics Inc will post ($1.87) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/edge-therapeutics-inc-edge-ceo-sells-27325-00-in-stock.html.
A number of brokerages have recently weighed in on EDGE. Zacks Investment Research cut shares of Edge Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. BidaskClub raised shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 3rd.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Edge Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after purchasing an additional 19,973 shares during the last quarter. Franklin Resources Inc. boosted its stake in Edge Therapeutics by 1.1% during the second quarter. Franklin Resources Inc. now owns 2,663,123 shares of the biotechnology company’s stock worth $27,324,000 after acquiring an additional 30,100 shares in the last quarter. Trexquant Investment LP bought a new position in Edge Therapeutics during the first quarter worth $143,000. Teachers Advisors LLC boosted its stake in Edge Therapeutics by 8.2% during the fourth quarter. Teachers Advisors LLC now owns 28,353 shares of the biotechnology company’s stock worth $354,000 after acquiring an additional 2,150 shares in the last quarter. Finally, Spark Investment Management LLC bought a new position in Edge Therapeutics during the first quarter worth $157,000. 49.38% of the stock is currently owned by institutional investors.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.